ADAR1 Capital Management LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD

ADAR1 Capital Management LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 38,955 shares of the biopharmaceutical company's stock, valued at approximately $986,000.

A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. acquired a new position in ACADIA Pharmaceuticals in the second quarter valued at approximately $569,634,000. Norges Bank acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth approximately $40,266,000. Millennium Management LLC lifted its position in shares of ACADIA Pharmaceuticals by 2,052.1% during the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company's stock worth $31,652,000 after buying an additional 1,414,315 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of ACADIA Pharmaceuticals by 390.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company's stock valued at $35,187,000 after buying an additional 1,312,426 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of ACADIA Pharmaceuticals by 47.3% in the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company's stock valued at $74,435,000 after buying an additional 1,073,834 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 14,292 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $29.22, for a total transaction of $417,612.24. Following the sale, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,981,934.16. The trade was a 17.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the company's stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total transaction of $432,660.54. Following the transaction, the executive vice president directly owned 18,994 shares in the company, valued at approximately $496,313.22. This trade represents a 46.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 36,699 shares of company stock valued at $1,019,894 in the last quarter. 26.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have commented on ACAD. BMO Capital Markets lifted their price target on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 21st. Citigroup raised their target price on shares of ACADIA Pharmaceuticals from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday. Weiss Ratings upgraded shares of ACADIA Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday, August 12th. UBS Group upped their price target on shares of ACADIA Pharmaceuticals from $45.00 to $49.00 and gave the company a "buy" rating in a research report on Monday, August 17th. Finally, Citizens Jmp increased their price target on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $34.36.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: The European Commission approved DAYBU® (trofinetide) as the first and only treatment authorized in the European Union for neurobehavioral symptoms associated with Rett syndrome. The approval covers adults and children aged five and older, giving ACADIA access to a significant new geographic market and potentially expanding the drug’s revenue opportunity. European Commission Approves DAYBU for Rett Syndrome
• Positive Sentiment: Analyst sentiment improved after Citigroup raised its ACADIA price target from $39 to $40 and upgraded or reaffirmed the stock with a “Buy” rating. The new target implies approximately 30.8% upside from the referenced price, signaling confidence in ACADIA’s commercial and earnings prospects. Citigroup Raises ACADIA Price Target
• Positive Sentiment: ACADIA received a consensus analyst recommendation of “Moderate Buy,” adding broader Wall Street support to the bullish case. ACADIA Receives Moderate Buy Consensus
• Neutral Sentiment: The reported short-interest update shows zero shares short both before and after the period, with a zero-day short-interest ratio and an undefined percentage change. Because the data appears inconsistent, it provides no meaningful signal about short-seller positioning.

ACADIA Pharmaceuticals Stock Performance

ACAD stock opened at $30.57 on Wednesday. ACADIA Pharmaceuticals Inc. has a one year low of $19.69 and a one year high of $30.96. The stock has a market capitalization of $5.27 billion, a PE ratio of 13.77, a price-to-earnings-growth ratio of 23.35 and a beta of 0.81. The company has a fifty day moving average of $26.32 and a 200-day moving average of $23.54.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The business had revenue of $308.00 million for the quarter, compared to the consensus estimate of $296.55 million. During the same quarter in the previous year, the firm earned $0.16 earnings per share. The business's quarterly revenue was up 16.4% compared to the same quarter last year. Equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.59 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source